Argent Biopharma 

Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer. The company was formerly known as MGC Pharmaceuticals Limited and changed it name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.